Computational Models for Activated Human MEK1: Identification of Key Active Site Residues and Interactions

MEK1 is a protein kinase in the MAPK cellular signaling pathway that is notable for its dual specificity and its potential as a drug target for a variety of cancer therapies. While much is known about the key role of MEK1 in signaling events, understanding of the structural features that sustain MEK1 function remains limited because of the absence of crystal or NMR structural insights into the phosphorylated and activated form of MEK1. In this work, homology modeling was used to overcome this limitation and generate computational models of the doubly phosphorylated active MEK1 conformation. A variety of models were generated using crystal structures of active protein kinases as homology model templates. These models were equilibrated using molecular dynamics simulations, and each model was validated against several known structural characteristics of activated kinases. The best model structures were used in docking studies with ATP and a small peptide sequence that represents the activation loop of ERK2 to identify the most important residues in stabilizing protein docking and phosphorylation. These results provide insights for the pursuit of structure-guided mutagenesis and drug design.

[1]  S. Li,et al.  Phosphorylation-Dependent Inhibition of Akt1 , 2018, Genes.

[2]  C. Zheng,et al.  Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues. , 1994, The EMBO journal.

[3]  Farren J. Isaacs,et al.  Robust production of recombinant phosphoproteins using cell-free protein synthesis , 2015, Nature Communications.

[4]  Kristina Lorenz,et al.  Phosphorylation or Mutation of the ERK2 Activation Loop Alters Oligonucleotide Binding. , 2016, Biochemistry.

[5]  Manfred J. Sippl,et al.  Thirty years of environmental health research--and growing. , 1996, Nucleic Acids Res..

[6]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[7]  Susan S. Taylor,et al.  Protein kinases: evolution of dynamic regulatory proteins. , 2011, Trends in biochemical sciences.

[8]  Lori A Burns,et al.  Levels of symmetry adapted perturbation theory (SAPT). I. Efficiency and performance for interaction energies. , 2014, The Journal of chemical physics.

[9]  M. Sippl.  Recognition of errors in three‐dimensional structures of proteins , 1993, Proteins.

[10]  Sam A. Johnson,et al.  Kinomics: methods for deciphering the kinome , 2004, Nature Methods.

[11]  M S Waterman,et al.  Identification of common molecular subsequences. , 1981, Journal of molecular biology.

[12]  J. Chin,et al.  Efficient genetic encoding of phosphoserine and its nonhydrolyzable analog. , 2015, Nature chemical biology.

[13]  Alexander D. MacKerell,et al.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. , 2012, Journal of chemical theory and computation.

[14]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[15]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[16]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[17]  Susan S. Taylor,et al.  Defining the Conserved Internal Architecture of a Protein Kinase , 2010, Biochimica et biophysica acta.

[18]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[19]  Christopher L. McClendon,et al.  Decoding the Interactions Regulating the Active State Mechanics of Eukaryotic Protein Kinases , 2016, PLoS biology.

[20]  P. Ascierto,et al.  MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors , 2017, American Journal of Clinical Dermatology.

[21]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[22]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[23]  C. Liebmann,et al.  Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. , 2001, Cellular signalling.

[24]  Ross C. Walker,et al.  An overview of the Amber biomolecular simulation package , 2013 .

[25]  Katsuyuki Kunida,et al.  Processive phosphorylation of ERK MAP kinase in mammalian cells , 2011, Proceedings of the National Academy of Sciences.

[26]  R. Seger,et al.  The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. , 2011, Biochimica et biophysica acta.

[27]  M. Graham,et al.  Syndapin I is the phosphorylation-regulated dynamin I partner in synaptic vesicle endocytosis , 2006, Nature Neuroscience.

[28]  Farren J. Isaacs,et al.  Encoding human serine phosphopeptides in bacteria for proteome-wide identification of phosphorylation-dependent interactions , 2018, Nature Biotechnology.

[29]  T. Schwede,et al.  Modeling protein quaternary structure of homo- and hetero-oligomers beyond binary interactions by homology , 2017, Scientific Reports.

[30]  K. Nagata,et al.  A decade of site‐ and phosphorylation state‐specific antibodies: recent advances in studies of spatiotemporal protein phosphorylation , 2001, Genes to cells : devoted to molecular & cellular mechanisms.

[31]  Matthew L. Leininger,et al.  Psi4: an open‐source ab initio electronic structure program , 2012 .

[32]  J. Zheng,et al.  Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. , 1991, Science.

[33]  R. Seger,et al.  The ERK signaling cascade—Views from different subcellular compartments , 2009, Biofactors.

[34]  Hiroto Yamaguchi,et al.  Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.

[35]  R. Roskoski.  MEK1/2 dual-specificity protein kinases: structure and regulation. , 2012, Biochemical and biophysical research communications.

[36]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[37]  Philippe P Roux,et al.  Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases , 2011, Microbiology and Molecular Reviews.

[38]  Tamar Schlick,et al.  Analysis of protein sequence/structure similarity relationships. , 2002, Biophysical journal.

[39]  S. Hubbard.  Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.

[40]  Alexander D. MacKerell,et al.  CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field , 2015, Journal of chemical theory and computation.

[41]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[42]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[43]  Wei Chen,et al.  Differential regulation and properties of MAPKs , 2007, Oncogene.

[44]  Ariana Peck,et al.  Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers , 2013, Nature.

[45]  R. Roskoski.  Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. , 2017, Pharmacological research.

[46]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..